Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Topics in Antiviral Medicine|May 18, 2013
CROI 2013: Advances in antiretroviral therapyBarbara S Taylor, Timothy J Wilkin, Noga Shalev, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 15, 2013
Translational research insights from completed HIV vaccine efficacy trialsHong-Van Tieu, Morgane Rolland, Scott M Hammer, et al.
Topics in Antiviral Medicine|June 20, 2012
Advances in antiretroviral therapySusan Olender, Timothy J Wilkin, Barbara S Taylor, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2011
Lessons drawn from recent HIV vaccine efficacy trialsJonathan D Fuchs, Magda E Sobieszczyk, Scott M Hammer, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|April 28, 2004
Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USAMagdalena E Sobieszczyk, Eoin P G Coakley, Timothy J Wilkin, et al.
AIDS Research and Human Retroviruses|April 20, 2013
In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalitiesHolly Janes, Peter Gilbert, Susan Buchbinder, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398Marc Pfister, Line Labbé, Scott M Hammer, et al.
HIV Clinical Trials|April 25, 2013
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of TreatmentXinyan Zhang, Peter W Hunt, Scott M Hammer, et al.
The Journal of Infectious Diseases|July 11, 2003
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trialsPeter B Gilbert, Victor G DeGruttola, Michael G Hudgens, et al.
The Journal of Infectious Diseases|January 1, 2003
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapyCamlin Tierney, Janet L Lathey, Cindy Christopherson, et al.
Pageof 8